Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients
ESMO Congress 2025
Domenica Lorusso, MD, PhD, of Humanitas University, discusses results of a preplanned analysis from the ROSELLA trial. In the phase III study, the addition of relacorilant to nab-paclitaxel significantly prolonged progression-free survival and showed a clinically meaningful improvement in overall survival in patients with platinum-resistant ovarian cancer. This subgroup analysis examined outcomes of patients with prior exposure to a PARP inhibitor—a population reported to exhibit a worse response to subsequent chemotherapy (Abstract LBA45).
The ASCO Post Staff
Andrew R. Clamp, MD, PhD, of The Christie NHS Foundation Trust, reviews results of the phase III ICON8B trial, which found that in patients with high-risk stage III to IV epithelial ovarian cancer, the use of dose-dense weekly paclitaxel in combination with every-3-week carboplatin and bevacizumab as first-line systemic therapy improved median overall survival compared to standard every-3-week dosing (Abstract 1064O).
The ASCO Post Staff
Emese Zsiros, MD, PhD, of Roswell Park Comprehensive Cancer Center, reviews results from the randomized, double-blind, phase III ENGOT-ov65/KEYNOTE-B96 trial. According to the study investigators, “Pembrolizumab in combination with weekly paclitaxel with or without bevacizumab demonstrated statistically significant and clinically meaningful improvement in progression-free survival regardless of PD-L1 status and in overall survival in participants with PD-L1–expressing tumor (CPS ≥ 1).... This is the first phase III study to report a statistically significant improvement in overall survival with an immune checkpoint inhibitor–based regimen in ovarian cancer.” (Abstract LBA3)
